Literature DB >> 35347580

Long-term survival analysis of sublobar resection versus lobectomy for older patients with early-stage pulmonary carcinoid tumour: a database-based propensity score-matched study.

Hao Yang1, Xinqi Xiao2, Tonghua Mei3, Ping Zhou4.   

Abstract

BACKGROUND: The optimal extent of surgery for older patients with early-stage pulmonary carcinoid tumour (PC) remains controversial. AIMS: To compare prognostic differences between sublobar resection versus lobectomy in older patients with early-stage PC.
METHODS: The SEER database was searched for stage T1N0M0 PC patients aged ≥ 65 years who underwent lobectomy or sublobar resection from 2000 to 2017. Propensity score matching (PSM) was used to determine intergroup covariate differences. Kaplan-Meier curves and the log-rank test were used for intergroup comparison of overall survival (OS). A Cox proportional hazard model was used to evaluate independent risk factors.
RESULTS: Among 1023 participants, 650 and 373 underwent lobectomy and sublobar resection, respectively. Before PSM, the 5- and 10-year OS in the sublobar resection group were lower than that of the lobectomy group (5-year OS 84.12% vs. 91.16%; 10-year OS 57.43% vs. 64.77%; p = 0.014); after PSM, no significant prognostic difference existed between lobectomy and sublobar resection (5-year OS 88.17% vs. 89.23%; 10-year OS 58.32% vs. 62.75%; p = 0.811). Subgroup analysis included tumour size, age, number of lymph nodes examined and histological type, and showed no statistically significant survival differences between the lobectomy and sublobar resection groups. Multivariable Cox analysis indicated that age ≥ 77 years, male sex, inadequate lymph node assessment (< 7), and atypical carcinoid were associated with reduced OS.
CONCLUSION: Sublobar resection showed a similar long-term survival rate for early-stage PC patients aged ≥ 65 years as with lobectomy, thereby providing a basis for the selection of surgical methods for PC.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Lobectomy; Older adults; Propensity score matching; Pulmonary carcinoid; SEER; Sublobar resection

Mesh:

Year:  2022        PMID: 35347580     DOI: 10.1007/s40520-022-02112-0

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   4.481


  38 in total

1.  Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  E Baudin; M Caplin; R Garcia-Carbonero; N Fazio; P Ferolla; P L Filosso; A Frilling; W W de Herder; D Hörsch; U Knigge; C M Korse; E Lim; C Lombard-Bohas; M Pavel; J Y Scoazec; A Sundin; A Berruti
Journal:  Ann Oncol       Date:  2021-01-19       Impact factor: 32.976

Review 2.  Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management.

Authors:  Talal Hilal
Journal:  Ther Adv Med Oncol       Date:  2016-11-17       Impact factor: 8.168

3.  Role of Adjuvant Chemotherapy in Pulmonary Carcinoids: An NCDB Analysis.

Authors:  Rohit Gosain; Adrienne Groman; Sai S Yendamuri; Renuka Iyer; Sarbajit Mukherjee
Journal:  Anticancer Res       Date:  2019-12       Impact factor: 2.480

4.  Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors.

Authors:  Daniel P Nussbaum; Paul J Speicher; Brian C Gulack; Matthew G Hartwig; Mark W Onaitis; Thomas A D'Amico; Mark F Berry
Journal:  Ann Thorac Surg       Date:  2014-12-10       Impact factor: 4.330

Review 5.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

6.  Incidence and Prognostic Significance of Carcinoid Lymph Node Metastases.

Authors:  Peter J Kneuertz; Mohamed K Kamel; Brendon M Stiles; Benjamin E Lee; Mohamed Rahouma; Sebron W Harrison; Nasser K Altorki; Jeffrey L Port
Journal:  Ann Thorac Surg       Date:  2018-06-15       Impact factor: 4.330

7.  Prognostic score for survival with pulmonary carcinoids: the importance of associating clinical with pathological characteristics.

Authors:  Marco Chiappetta; Isabella Sperduti; Leonardo Petracca Ciavarella; Giovanni Leuzzi; Emilio Bria; Felice Mucilli; Filippo Lococo; Pierluigi Filosso; Giovannibattista Ratto; Lorenzo Spaggiari; Francesco Facciolo; Stefano Margaritora
Journal:  Interact Cardiovasc Thorac Surg       Date:  2020-09-01

8.  Pulmonary carcinoid tumours: incidence, histology, and surgical outcome. A population-based study.

Authors:  Astridur Petursdottir; Johanna Sigurdardottir; Bjorn M Fridriksson; Arni Johnsen; Helgi J Isaksson; Hronn Hardardottir; Steinn Jonsson; Tomas Gudbjartsson
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-11-28

9.  Lobar versus sub-lobar surgery for pulmonary typical carcinoid, a population-based analysis.

Authors:  Muhammad Furqan; Yu-Yu Tien; Mary C Schroeder; Kalpaj R Parekh; John Keech; Bryan G Allen; Alexandra Thomas; Jun Zhang; Gerald Clamon; Taher Abu Hejleh
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 10.  Recent Advances in the Management of Typical and Atypical Lung Carcinoids.

Authors:  Natalie Prinzi; Roberta Elisa Rossi; Claudia Proto; Giovanni Leuzzi; Alessandra Raimondi; Martina Torchio; Massimo Milione; Francesca Corti; Elena Colombo; Michele Prisciandaro; Tommaso Cascella; Carlo Spreafico; Teresa Beninato; Jorgelina Coppa; Giuseppe Lo Russo; Maria Di Bartolomeo; Filippo de Braud; Sara Pusceddu
Journal:  Clin Lung Cancer       Date:  2020-12-17       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.